Microplastics and Misinformation: What Science Really Says
November 12, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
No Data Available.
Synonyms :
efavirenz
Class :
Antiviral agents and Anti-HIV (antiretroviral)
Brand Name :
No Data Available.
Synonyms :
efavirenz
Class :
Antiviral agents and Anti-HIV (antiretroviral)
Dosage Forms & StrengthsÂ
Tablet, Oral:Â
50 mgÂ
200 mg Â
Capsule, Oral:Â
600 mgÂ
600
mg
Orally 
once a day
in combination with tenofovir and lamivudine
Discontinue therapy immediately, if moderate to severe hepatic impairment is noticed
Note: Not recommended to use in combination with abacavir and lamivudine, especially for patients receiving pre-antiretroviral therapy
Dosage Forms & StrengthsÂ
Tablet, Oral:Â
50 mgÂ
200 mg Â
Capsule, Oral:Â
600 mgÂ
Note: Not recommended to use in combination with abacavir and lamivudine, especially for patients receiving pre-antiretroviral therapy
Not recommended for <3 months infants
Oral Dose instructions based on weight:
10 kg to <15 kg: 200 mg/day orally
15 kg to <20 kg: 250 mg/day orally
20 kg to <25 kg: 300 mg/day orally
25 kg to 32.5 kg: 350 mg/day orally
32.5 to <40 kg: 400 mg/day orally
>40 kg: 600 mg/day orally
Discontinue therapy immediately, if moderate to severe hepatic impairment noticed
Refer to adult dosingÂ
may enhance the QTc-prolonging effect of QT-prolonging agents
may enhance the QTc-prolonging effect of QT-prolonging agents
may enhance the QTc-prolonging effect of QT-prolonging agents
may enhance the QTc-prolonging effect of QT-prolonging agents
may enhance the QTc-prolonging effect of QT-prolonging agents
It may diminish the effect when combined with lonafarnib by affecting CYP3A4 metabolism
efavirenz: they may diminish the serum concentration of hormonal contraceptives
efavirenz: they may diminish the serum concentration of hormonal contraceptives
efavirenz: they may diminish the serum concentration of hormonal contraceptives
efavirenz: they may diminish the serum concentration of hormonal contraceptives
efavirenz: they may diminish the serum concentration of rifabutin
may diminish the concentration of serum when combined with cannabinoid products
may diminish the concentration of serum when combined with cannabinoid products
may diminish the serum concentration when combined with hormonal contraceptives
may diminish the serum concentration when combined with hormonal contraceptives
may diminish the serum concentration when combined with hormonal contraceptives
may diminish the serum concentration when combined with hormonal contraceptives
efavirenz: they may diminish the serum concentration of hormonal contraceptives
efavirenz: they may diminish the serum concentration of hormonal contraceptives
may diminish the serum concentration when combined with hormonal contraceptives
may diminish the serum concentration when combined with hormonal contraceptives
may increase the serum concentration of CYP3A4 substrates
it decreases by affecting the hepatic enzyme CYP3A4 metabolism
may enhance the serum concentrations of active metabolites
may diminish the serum concentration
may diminish the serum concentration
budesonide and formoterol (inhalation)Â
may enhance the serum concentration of CYP3A4 inhibitor
may diminish the serum concentration of CYP3A4 inducers
may diminish the serum concentration of CYP3A4 inducers
may decrease the serum concentration when combined with CYP3A4 Inducers (Strong)
may increase or decrease the activity of this enzyme when combined with sparsentan
may diminish the serum concentration when combined with alfentanil
may diminish the serum concentration when combined with apixaban
may diminish the serum concentration when combined with aripiprazole
may diminish the serum concentration when combined with atogepant
may diminish the serum concentration when combined with belumosudil
may diminish the serum concentration when combined with ubrogepant
may diminish the serum concentration when combined with fenfluramine
may increase the QTc prolonging effect of QT-prolonging Class III Antiarrhythmics
brexpiprazole : they may diminish the serum concentration of CYP3A4 Inducers
CYP2C19 Inducers: they may diminish the serum concentration of brivaracetam
cabozantinib :they may diminish the serum concentration of CYP3A4 Inducers
clarithromycin: they may enhance serum concentrations of CYP3A4 Inducers
cyclosporin: they may diminish the serum concentration of CYP3A4 Inducers
dexamethasone: they may diminish the serum concentration of CYP3A4 Inducers
diltiazem: they may diminish the serum concentration of CYP3A4 Inducers
enzalutamide: they may diminish serum concentrations of the active metabolites of CYP3A4 inducers
CYP3A4 inducers: they may diminish the serum concentration of eravacycline
erlotinib: they may diminish the serum concentration of CYP3A4 inducers
exemestane: they may diminish the serum concentration of CYP3A4 Inducers
felodipine: they may diminish the serum concentration of CYP3A4 Inducers
CYP3A4 inducers: they may diminish the serum concentration of ganaxolone
may diminish the serum concentration of zanubrutnib
drospirenone/ethinyl estradiol/levomefolateÂ
may diminish the serum concentration of Hormonal Contraceptives
may diminish the serum concentration of Voxelotor
may diminish the serum concentration of Voxelotor
brigatinib: they may diminish the serum concentration of CYP3A4 Inducers
daclatasvir: they may diminish the serum concentration of CYP3A4 Inducers
guanfacine: they may diminish the serum concentration of CYP3A4 Inducers
CYP3A4 Inducers: they may diminish the serum concentration of larotrectinib
lefamulin: they may diminish the serum concentration of CYP3A4 Inducers
lorlatinib: they may increase the hepatotoxic effect of CYP3A4 Inducers
lurasidone: they may diminish the serum concentration of CYP3A4 Inducers
maraviroc: they may diminish the serum concentration of CYP3A4 Inducers
mitapivat: they may diminish the serum concentration of CYP3A4 Inducers
perampanel: they may diminish the serum concentration of CYP3A4 Inducers
pirtobrutinib: they may diminish the serum concentration of CYP3A4 Inducers
ripretinib: they may diminish the serum concentration of CYP3A4 Inducers
empagliflozin and linagliptinÂ
may diminish the serum concentration when combined
may decrease the therapeutic effect when combined
lonafarnib: they may enhance the serum concentration of CYP3A4 Inhibitors
sirolimus: they may enhance the serum concentration of CYP3A4 Inhibitors
may diminish the concentration of serum when combined with methylprednisolone
may diminish the serum concentration of Hormonal Contraceptives
etonogestrel/ethinyl estradiolÂ
may diminish the serum concentration of Hormonal Contraceptives
dalfampridine: they may enhance the serum concentration of OCT1 Inhibitors
budesonide: they may enhance the serum concentration of CYP3A4 Inhibitors
It may diminish the levels when combined with efavirenz by CYP3A4 metabolism
It may diminish the levels when combined with efavirenz by CYP3A4 metabolism
It may diminish the levels when combined with efavirenz by CYP3A4 metabolism
It may diminish the levels when combined with efavirenz by CYP3A4 metabolism
It may diminish the levels when combined with efavirenz by enhancing metabolism
It may diminish the levels when combined with efavirenz by CYP3A4 metabolism
ripretinib: they may diminish the serum concentration of CYP3A4 Inducers
alfentanil: they may enhance the serum concentration of CYP3A Inhibitors
budesonide: they may enhance the serum concentration of CYP3A Inhibitors
bromocriptine: they may enhance the serum concentration of CYP3A Inhibitors
cilostazol: they may enhance the serum concentration of CYP3A Inhibitors
cisapride: they may enhance the serum concentration of CYP3A Inhibitors
colchicine: they may enhance the serum concentration of CYP3A Inhibitors
dapoxetine: they may enhance the serum concentration of CYP3A Inhibitors
eliglustat: they may enhance the serum concentration of CYP3A Inhibitors
fentanyl: they may enhance the serum concentration of CYP3A Inhibitors
lumateperone: they may enhance the serum concentration of CYP3A Inhibitors
mitapivat: they may enhance the serum concentration of CYP3A Inhibitors
naloxegol: they may enhance the serum concentration of CYP3A Inhibitors
omaveloxolone: they may enhance the serum concentration of CYP3A Inhibitors
pexidartinib: they may enhance the serum concentration of CYP3A Inhibitors
ranolazine: they may enhance the serum concentration of CYP3A4 Inducers
rimegepant: they may enhance the serum concentration of CYP3A Inhibitors
sirolimus: they may enhance the serum concentration of CYP3A4 Inducers
suvorexant: they may enhance the serum concentration of CYP3A Inhibitors
tolvaptan: they may enhance the serum concentration of CYP3A Inhibitors
triazolam: they may enhance the serum concentration of CYP3A4 Inducers
zanubrutinib: they may enhance the serum concentration of CYP3A Inhibitors
may diminish the serum concentration when combined with hormonal contraceptives
may diminish the serum concentration when combined with hormonal contraceptives
may diminish the serum concentration when combined with hormonal contraceptives
aclidinium: they may enhance the serum concentration of CYP3A Inhibitors
simvastatin: it may diminish the serum concentration of CYP3A4 Inducers
may increase the levels of serum concentration of ergot derivatives
may increase the levels of serum concentration of ergot derivatives
may increase the levels of serum concentration of ergot derivatives
may increase the levels of serum concentration of ergot derivatives
may increase the levels of serum concentration of ergot derivatives
It may diminish the effect when combined with pemigatinib by affecting CYP3A4 metabolism
It may diminish the effect when combined with irinotecan liposomal by affecting CYP3A4 metabolism
It may diminish the effect when combined with lumateperone by affecting CYP3A4 metabolism
it may enhance the qtc interval when combined with lofexidine
It may diminish the level when combined with efavirenz by affecting CYP3A4 metabolism
may diminish the serum concentration of each other when combined
may diminish the serum concentration of each other when combined
may diminish the serum concentration of each other when combined
may diminish the serum concentration of each other when combined
may diminish the serum concentration of each other when combined
when both drugs are combined, there may be a decreased level of serum concentration of alpelisib   
QTc interval increases on taking efavirenz and lenvatinib together. Avoid or take an alternate drug
the effect of efavirenz is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
efavirenz decreases the effect of ixazomib by altering intestinal/hepatic CYP3A4 enzyme metabolism
when both drugs are combined, there may be an increased QTC interval  
CYP3A strong enhancers of the small intestine may reduce the bioavailability of efavirenz
efavirenz decreases the effect of fedratinib by altering the intestinal/hepatic CYP3A4 enzyme metabolism
it will decrease the impact or level of regorafenib by altering the intestinal or hepatic CYP3A4 enzyme metabolism
it enhances by affecting the hepatic enzyme CYP2C9 metabolism
it increases the concentration of CYP3A4 substrates in the serum
it increases the concentration of CYP3A4 substrates in serum
relugolix/​estradiol/​norethindroneÂ
it decreases by affecting the hepatic enzyme CYP3A4 metabolism
it decreases by affecting the hepatic enzyme CYP3A4 metabolism
it increases the concentration of CYP3A4 substrates in the serum
it increases the concentration of OCT1 substrates in the serum
may diminish the serum concentration
may diminish the serum concentration
may enhance the serum concentration
they decrease the concentration of rilpivirine
may decrease the serum concentration of macimorelin
may enhance the serum concentration
may decrease the serum concentration of lenacapavir
may enhance the serum concentration
they decrease the concentration of buprenorphine in the serum
may diminish the serum concentration of CYP3A4 inducers
may diminish the serum concentration of CYP3A4 inducers
may diminish the serum concentration of CYP3A4 inducers
may diminish the serum concentration of CYP3A4 inducers
may diminish the serum concentration of CYP3A4 inducers
may diminish the serum concentration of CYP3A4 inducers
may diminish serum concentrations of CYP3A4 inducers
may diminish the serum concentration of CYP3A4 inducers
they decrease the concentration of glasdegib in the serum
it increases the concentration of CYP3A4 substrates in the serum
it increases the concentration of CYP3A4 substrates in the serum
they decrease the concentration of active metabolites of infigratinib in the serum
may enhance the serum concentration of elbasvir/grazoprevir
may decrease the serum concentration of elbasvir/grazoprevir
it increases the concentration of CYP3A4 substrates in the serum
It may enhance QTc interval when combined with pentamidine
abrocitinib: they may diminish the serum concentration of CYP2C19 Inducers
CYP3A4 Inducers: they may diminish the serum concentration of capmatinib
ceritinib: they may diminish the serum concentration of CYP3A4 Inducers
crizotinib: they may diminish the serum concentration of CYP3A4 Inducers
duvelisib: they may diminish the serum concentration of CYP3A4 Inducers
The serum concentration of Avacopan may be decreased by strong CYP3A4 inducers
they decrease the concentration of lurbinectedin in the serum
they decrease the concentration of lurbinectedin in the serum
CYP3A4 inducers decrease the concentration of nimodipine in the serum
may diminish the concentration of serum when combined with lemborexant
may enhance the concentration of serum when combined with CYP3A4 substrates
may enhance the concentration of serum when combined with CYP3A4 substrates
bosutinib: they may diminish the serum concentration of CYP3A4 Inducers
cariprazine: they may diminish the serum concentration of CYP3A4 Inducers
cobimetinib: they may diminish the serum concentration of CYP3A4 Inducers
daridorexant: they may diminish the serum concentration of CYP3A4 Inducers
deflazacort: they may diminish serum concentrations of CYP3A4 Inducers
CYP3A4 Inducers: they may diminish the serum concentration of elacestrant
fedratinib: they may diminish the serum concentration of CYP3A4 Inducers
flibanserin: they may diminish the serum concentration of CYP3A4 Inducers
ibrexafungerp: they may diminish the serum concentration of CYP3A4 Inducers
ivabradine: they may diminish the serum concentration of CYP3A4 Inducers
mavacamten: they may diminish the serum concentration of CYP3A4 Inducers
neratinib: they may diminish the serum concentration of CYP3A4 Inducers
olaparib: they may diminish the serum concentration of CYP3A4 Inducers
olutasidenib: they may diminish the serum concentration of CYP3A4 Inducers
omaveloxolone: they may diminish the serum concentration of CYP3A4 Inducers
pemigatinib: they may diminish the serum concentration of CYP3A4 Inducers
rimegepant: they may diminish the serum concentration of CYP3A4 Inducers
ulipristal: they may diminish the serum concentration of CYP3A4 Inducers
venetoclax: they may diminish the serum concentration of CYP3A4 Inducers
voclosporin: they may diminish the serum concentration of CYP3A4 Inducers
vonoprazan fumarate: they may enhance the serum concentration of CYP3A4 Inducers
vorapaxar: they may diminish the serum concentration of CYP3A4 Inducers
pimozide: they may enhance the serum concentration of CYP3A4 Inhibitors
may enhance the concentration of serum when combined with mavacamten
may diminish the serum concentration of each other when combined
may diminish the serum concentration when combined
may diminish the concentration of serum when combined with antihepaciviral products
may diminish the concentration of serum when combined with axitinib
may diminish the concentration of serum when combined with dasabuvir
may diminish the concentration of serum when combined with entrectinib
It may enhance the level when combined with efavirenz by affecting CYP3A4 metabolism
It may diminish the level when combined with efavirenz by affecting CYP3A4 metabolism
It may diminish the level when combined with efavirenz by affecting CYP3A4 metabolism
It may enhance QTc interval when combined with efavirenz
It may enhance QTc interval when combined with efavirenz
It may diminish the effect when combined with efavirenz affecting CYP3A4 metabolism
It may diminish the effect when combined with efavirenz affecting CYP3A4 metabolism
It may diminish the levels when combined with efavirenz by CYP3A4 metabolism
It may diminish the levels when combined with efavirenz by CYP3A4 metabolism
It may enhance the QTc interval when combined with efavirenz
It may enhance the QTc interval when combined with efavirenz
It may enhance the QTc interval when combined with efavirenz
It may enhance the QTc interval when combined with efavirenz
It may enhance the QTc interval when combined with efavirenz
may altering the drug metabolism when combined with kratom
fexinidazole: they may enhance the serum concentration of CYP3A4 inhibitors
fusidic acid: they may enhance the serum concentration of CYP3A inhibitors
trabectedin: they may diminish the serum concentration of CYP3A Inhibitors
asunaprevir: they may enhance the serum concentration of CYP3A Inhibitors
bosutinib: they may enhance the serum concentration of CYP3A Inhibitors
elacestrant: they may enhance the serum concentration of CYP3A Inhibitors
fosaprepitant: they may enhance the serum concentration of CYP3A Inhibitors
infigratinib: they may diminish serum concentrations of CYP3A Inhibitors
lemborexant: they may enhance the serum concentration of CYP3A Inhibitors
methysergide: they may enhance the serum concentration of CYP3A Inhibitors
simeprevir: they may enhance the serum concentration of CYP3A Inhibitors
antiretroviral agents undergo intracellular phosphorylation that will reduce the efficacy of cladribine
benzthiazide: it may increase the risk of adverse effects with CYP3A inhibitors
betaine: it may increase the risk of adverse effects with CYP3A inhibitors
carboplatin: it may increase the risk of adverse effects with CYP3A inhibitors
carfilzomib: it may increase the risk of adverse effects with CYP3A inhibitors
dactinomycin: it may increase the risk of adverse effects with CYP3A inhibitors
dapagliflozin: it may increase the risk of adverse effects with CYP3A inhibitors
CYP3A4 Inducers may decrease the levels of serum concentration of hormonal contraceptives
CYP3A4 Inducers may decrease the levels of serum concentration of hormonal contraceptives
CYP3A4 Inducers may decrease the levels of serum concentration of hormonal contraceptives
CYP3A4 Inducers may decrease the levels of serum concentration of hormonal contraceptives
may reduce the level of serum concentration of estrogen drugs
bazedoxifene/conjugated estrogens
may reduce the level of serum concentration of estrogen drugs
may reduce the level of serum concentration of estrogen drugs
may reduce the level of serum concentration of estrogen drugs
may reduce the level of serum concentration of estrogen drugs
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
May decrease the serum concentration
May decrease the serum concentration
May decrease the serum concentration
May decrease the serum concentration
May decrease the serum concentration
may increase the serum concentration
may increase the serum concentration
bazedoxifene/conjugated estrogens
may increase the serum concentration
synthetic conjugated estrogens, a
may increase the serum concentration
synthetic conjugated estrogens, b
may increase the serum concentration
may increase the serum concentration
may increase the QTc-prolonging effect
may increase the QTc-prolonging effect
may increase the QTc-prolonging effect
may increase the QTc-prolonging effect
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentrations
may increase the levels of serum concentrations
may increase the levels of serum concentrations
may increase the levels of serum concentrations
may increase the levels of serum concentrations
may decrease the levels of serum concentrations
may decrease the levels of serum concentrations
may decrease the levels of serum concentrations
may decrease the levels of serum concentrations
may decrease the levels of serum concentrations
may decrease the levels of serum concentrations
may decrease the levels of serum concentrations
may decrease the levels of serum concentrations
may decrease the levels of serum concentrations
may decrease the levels of serum concentrations
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may decrease the levels of serum concentration
acetaminophen and phenyltoloxamine
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
acetaminophen and phenyltoloxamine
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may reduce the levels of serum concentration
may reduce the levels of serum concentration
may reduce the levels of serum concentration
may reduce the levels of serum concentration
may reduce the levels of serum concentration
may reduce the levels of serum concentration
may reduce the levels of serum concentration
may reduce the levels of serum concentration
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may decrease the levels of serum concentration
It may enhance the levels when combined with tamsulosin by affecting CYP3A4 metabolism
may decrease the serum concentration
may decrease the serum concentration
may decrease the serum concentration
may decrease the serum concentration
may decrease the serum concentration
may decrease the serum concentration
may decrease the serum concentration
may decrease the serum concentration
may decrease the serum concentration
may decrease the serum concentration
may decrease the serum concentration
may decrease the serum concentration
may decrease the serum concentration
may decrease the serum concentration
may decrease the serum concentration
may decrease the serum concentration
may increase the serum concentration
may increase the serum concentration
may increase the serum concentration
may increase the serum concentration
may increase the serum concentration
may decrease the serum concentration
may decrease the serum concentration
may decrease the serum concentration
may decrease the serum concentration
may decrease the serum concentration
may decrease the serum concentration
may decrease the serum concentration
may decrease the serum concentration
may decrease the serum concentration
may decrease the serum concentration
efavirenz together with cisapride lead to an elevation of the QTc interval
When alprazolam and efavirenz is used together, this leads to reduction in the alprazolam’s metabolism
When dexrabeprazole and efavirenz is used together, this leads to reduction in the dexrabeprazole’s metabolism
When acetohexamide is used together with efavirenz, this lead to reduction in acetohexamide’s metabolism
When efavirenz is used together with somatotropin, this leads to a rise in efavirenz metabolism
When efavirenz is used together with melitracen, this leads to enhanced risk or seriousness of CNS depression
When efavirenz is used together with adenosine, this leads to enhanced risk or seriousness of QTc prolongation
When acepromazine is used together with efavirenz, this leads to enhanced risk or seriousness of CNS depression
it may decrease the levels of serum concentration
it may decrease the levels of serum concentration
it may decrease the levels of serum concentration
it may decrease the levels of serum concentration
it may decrease the levels of serum concentration
may enhance the CNS depressant effect
may enhance the CNS depressant effect
may enhance the CNS depressant effect
may enhance the CNS depressant effect
may enhance the CNS depressant effect
when both drugs are combined, there may be a decreased metabolism of etoposide   
when both drugs are combined, there may be a decreased metabolism of paclitaxel 
when both the drugs are combined, the metabolism of carmustine decreases    
interaction with trimetrexate may increase liver toxicity, induce vomiting and abdominal pain
has a synergistic effect over brentuximab vedotin, by showing altered intestinal/hepatic CYP3A4 enzyme metabolism.
increases serum level of cabazitaxel by affecting the enzyme CYP3A4
may reduce therapeutic effects of docetaxel
encorafenib increases the toxicity of efavirenz and decreases its effectiveness by altering intestinal/hepatic CYP3A4 enzyme metabolism
efavirenz decreases the effect of gefitinib by altering the intestinal/ hepatic CYP3A4 enzyme metabolism
it increases the effect or level of palbociclib by altering the intestinal or hepatic CYP3A4 enzyme metabolism
QT-prolonging Agents may enhance the QTc-prolonging effect of haloperidol
fexinidazole may enhance the QTc-prolonging effect of QT-prolonging Agents
may enhance the serum concentration of CYP3A4 inhibitors
may decrease the levels of serum concentration of clozapine
may increase the levels of serum concentrations of clobazam
hydrocodone/​chlorpheniramine/​pseudoephedrineÂ
may diminish the serum concentration
it increases the concentration of OCT1 substrates in the serum
may increase the serum concentration
may increase the serum concentration of CYP3A4 substrates
may increase the serum concentration of erdafitinib
may decrease the serum concentration of erdafitinib.
it decreases the concentration of antiretroviral agent in the serum
azelastine/fluticasone intranasalÂ
may enhance the serum concentration
may decrease the serum concentration of macitentan
may decrease the level of serum concentration of pretomanid
may decrease the serum concentration of CYP2C9 substrates
CYP3A4 Inducers may decrease the serum concentration of eliglustat
may decrease the serum concentration of encorafenib
may decrease the serum concentration of estazolam
may decrease the serum concentration of estrogen derivatives
bazedoxifene/conjugated estrogens
may decrease the serum concentration of estrogen derivatives
may decrease the serum concentration of estrogen derivatives
may decrease the serum concentration of estrogen derivatives
may decrease the serum concentration of estrogen derivatives
may increase the serum concentration of abemaciclib
may diminish the serum concentration of corticosteroids
may enhance the serum concentration of CYP2C19 Inhibitors
may diminish the serum concentration of CYP3A4 inducers
may diminish the serum concentration of CYP3A4 inducers
may diminish the serum concentration of CYP3A4 inducers
may diminish the serum concentration of CYP3A4 inducers
may diminish the serum concentration of CYP3A4 inducers
may diminish the serum concentration of CYP3A4 inducers
may diminish the serum concentration of CYP3A4 inducers
may diminish the serum concentration of CYP3A4 inducers
may diminish the serum concentration of CYP3A4 inducers
may decrease the level of serum concentrations of itraconazole
CYP3A4 inhibitors increase the concentration of carbamazepine in the serum
CYP3A4 inhibitors increase the concentration of iloperidone in the serum
may diminish the serum concentration when combined with selpercatinib
may diminish the serum concentration when combined with upadacitinib
may enhance the serum concentration of flibanserin
may increase the serum concentration of active metabolites
CYP3A4 inhibitors increase the concentration of rivaroxaban
may reduce the levels of serum concentration of tivozanib
may diminish the serum concentration when combined with tolvaptan
may diminish the serum concentration of Sulfonylureas
may increase the serum concentration of Lidocaine
may diminish the serum concentration of lidocaine
may increase the levels of serum concentration of pimavanserin
may diminish the serum concentration when combined with nintedanib
may diminish the serum concentration when combined with ziprasidone
may enhance the serum concentration when combined
eszopiclone: they may diminish the serum concentration of CYP3A4 Inducers
ethosuximide: they may diminish the serum concentration of CYP3A4 Inducers
hydrocodone: they may diminish the serum concentration of CYP3A4 Inducers
mefloquine: they may diminish the serum concentration of CYP3A4 Inducers
meperidine: they may diminish the serum concentration of CYP3A4 Inducers
methadone: they may diminish the serum concentration of CYP3A4 Inducers
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
bazedoxifene/conjugated estrogens
may increase the levels of serum concentration
synthetic conjugated estrogens, a
may increase the levels of serum concentration
synthetic conjugated estrogens, b
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may enhance the serum concentration of Buprenorphine
estrogens esterified/methyltestosterone            Â
may increase the thrombogenic effect of androgens
estrogens esterified/methyltestosterone            Â
may diminish the serum concentration when combined
It may enhance the serum concentration when combined with CYP3A4 Inhibitors
It may enhance the serum concentration when combined with CYP2C19 Inhibitors
It may enhance the serum concentration when combined with CYP2C9 Inhibitors
It may enhance the serum concentration when combined with CYP2C9 Inhibitors
It may enhance the serum concentration when combined with CYP2C9 Inhibitors
It may enhance the serum concentration when combined with CYP2C9 Inhibitors
It may enhance the serum concentration when combined with CYP2C9 Inhibitors
may enhance the concentration of serum when combined with fluticasone
it may increase the levels of serum concentration
it may increase the levels of serum concentration
it may increase the levels of serum concentration
it may increase the levels of serum concentration
it may increase the levels of serum concentration
it may increase the levels of serum concentration
it may increase the levels of serum concentration
it may increase the levels of serum concentration
it may increase the levels of serum concentration
it may increase the levels of serum concentration
it may increase the levels of serum concentration
it may increase the levels of serum concentration
alprazolam: they may diminish the serum concentration of CYP3A4 Inducers
aprepitant: they may diminish the serum concentration of CYP3A4 Inducers
codeine: they may diminish serum concentrations of CYP3A4 Inducers
copanlisib: they may diminish the serum concentration of CYP3A4 Inducers
omeprazole: they may diminish the serum concentration of CYP2C19 Inducers
diazepam: they may diminish the serum concentration of CYP3A4 Inducers
disopyramide: they may diminish the serum concentration of CYP3A4 Inducers
elvitegravir: they may diminish the serum concentration of CYP3A4 Inducers
everolimus: they may diminish the serum concentration of CYP3A4 Inducers
fentanyl: they may diminish the serum concentration of CYP3A4 Inducers
ibrutinib: they may diminish the serum concentration of CYP3A4 Inducers
idelalisib: they may diminish the serum concentration of CYP3A4 Inducers
ifosfamide: they may diminish serum concentrations of CYP3A4 Inducers
imatinib: they may diminish the serum concentration of CYP3A4 Inducers
lapatinib: they may diminish the serum concentration of CYP3A4 Inducers
lercanidipine: they may diminish the serum concentration of CYP3A4 Inducers
levamlodipine: they may diminish the serum concentration of CYP3A4 Inducers
mianserin: they may diminish the serum concentration of CYP3A4 Inducers
midazolam: they may diminish the serum concentration of CYP3A4 Inducers
may diminish the concentration of serum when combined with istradefylline
may enhance the serum concentration of Vitamin D Analogs
midostaurin: they may diminish the serum concentration of CYP3A4 Inducers
naldemedine: they may diminish the serum concentration of CYP3A4 Inducers
naloxegol: they may diminish the serum concentration of CYP3A4 Inducers
osimertinib: they may diminish the serum concentration of CYP3A4 Inducers
oxycodone: they may diminish the serum concentration of CYP3A4 Inducers
prednisone: they may diminish the serum concentration of CYP3A4 Inducers
quetiapine: they may diminish the serum concentration of CYP3A4 Inducers
quinidine: they may diminish the serum concentration of CYP3A4 Inducers
quinine: they may diminish the serum concentration of CYP3A4 Inducers
regorafenib: they may diminish the serum concentration of CYP3A4 Inducers
repaglinide: they may diminish the serum concentration of CYP3A4 Inducers
ribociclib: they may diminish the serum concentration of CYP3A4 Inducers
samidorphan: they may diminish the serum concentration of CYP3A4 Inducers
sorafenib: they may diminish the serum concentration of CYP3A4 Inducers
thiotepa: they may enhance serum concentrations of CYP3A4 Inducers
ticagrelor: they may diminish serum concentrations of CYP3A4 Inducers
toremifene: they may diminish serum concentrations of CYP3A4 Inducers
trabectedin: they may diminish the serum concentration of CYP3A4 Inducers
tramadol: they may diminish the serum concentration of CYP3A4 Inducers
trazodone: they may diminish the serum concentration of CYP3A4 Inducers
tucatinib: they may diminish the serum concentration of CYP3A4 Inducers
vemurafenib: they may diminish the serum concentration of CYP3A4 Inducers
verapamil: they may diminish the serum concentration of CYP3A4 Inducers
vilazodone: they may diminish the serum concentration of CYP3A4 Inducers
zolpidem: they may diminish the serum concentration of CYP3A4 Inducers
zopiclone: they may diminish the serum concentration of CYP3A4 Inducers
may decrease the concentration of serum when combined with methylergometrine
alprazolam: they may enhance the serum concentration of CYP3A4 Inhibitors
flibanserin: they may enhance the serum concentration of CYP3A Inhibitors
dofetilide: they may enhance the serum concentration of CYP3A Inhibitors
finerenone: they may enhance the serum concentration of CYP3A Inhibitors
midazolam: they may enhance the serum concentration of CYP3A Inhibitors
simvastatin: they may enhance serum concentrations of CYP3A Inhibitors
fusidic acid and betamethasoneÂ
may enhance the serum concentration when combined
may enhance the concentration of serum when combined with belzutifan
may enhance the concentration of serum when combined with brivaracetam
may diminish the concentration of serum when combined with clopidogrel
may enhance the concentration of serum when combined with dexlansoprazole
may enhance the concentration of serum when combined with lansoprazole
may diminish the serum concentration of each other when combined
may diminish the serum concentration of each other when combined
may diminish the concentration of serum when combined with aripiprazole lauroxil
may diminish the concentration of serum when combined with artemether and lumefantrine
may diminish the concentration of serum when combined with atazanavir
benzhydrocodone/acetaminophenÂ
may diminish the concentration of serum when combined with benzhydrocodone
It may diminish the level when combined with efavirenz by affecting CYP3A4 metabolism
It may enhance QTc interval when combined with efavirenz
It may diminish the effect when combined with efavirenz affecting CYP3A4 metabolism
It may diminish the effect when combined with efavirenz affecting CYP3A4 metabolism
clofarabine: they may enhance the serum concentration of OCT1 Inhibitors
It may enhance the QTc interval when combined with efavirenz
It may enhance the QTc interval when combined with efavirenz
It may enhance the QTc interval when combined with efavirenz
It may enhance the QTc interval when combined with efavirenz
It may enhance the QTc interval when combined with efavirenz
It may enhance the QTc interval when combined with efavirenz
It may enhance the QTc interval when combined with efavirenz
it decreases the concentration of CYP3A4 inducers in serum
clofazimine: they may enhance the serum concentration of CYP3A inhibitors
It may enhance the serum concentration when combined with CYP3A4 Substrates
It may enhance the serum concentration when combined with CYP3A4 Substrates
It may enhance the risk of adverse reactions when combined with Histamine antagonists
alfuzosin: they may enhance the serum concentration of CYP3A Inhibitors
alitretinoin: they may enhance the serum concentration of CYP3A Inhibitors
amiodarone: they may enhance the serum concentration of CYP3A Inhibitors
atorvastatin: they may enhance the serum concentration of CYP3A Inhibitors
axitinib: they may enhance the serum concentration of CYP3A Inhibitors
barnidipine: they may enhance the serum concentration of CYP3A Inhibitors
bedaquiline: they may enhance serum concentrations of CYP3A Inhibitors
benidipine: they may enhance the serum concentration of CYP3A Inhibitors
buprenorphine: they may enhance the serum concentration of CYP3A Inhibitors
cabozantinib: they may enhance the serum concentration of CYP3A Inhibitors
crizotinib: they may enhance the serum concentration of CYP3A Inhibitors
isavuconazonium sulfate: they may diminish serum concentrations of CYP3A Inhibitors
ebastine: they may enhance the serum concentration of CYP3A Inhibitors
felodipine: they may enhance the serum concentration of CYP3A inhibitors
gilteritinib: they may enhance the serum concentration of CYP3A inhibitors
macitentan: they may enhance the serum concentration of CYP3A Inhibitors
manidipine: they may enhance the serum concentration of CYP3A Inhibitors
salmeterol: they may enhance the serum concentration of CYP3A Inhibitors
nicardipine: they may diminish the serum concentration of CYP3A4 Inducers
clopidogrel: they may diminish the serum concentration of CYP3A4 Inducers
dapoxetine: they may diminish the serum concentration of CYP3A4 Inducers
cimetidine: they may diminish the serum concentration of CYP3A4 Inducers
diazoxide: they may diminish the serum concentration of CYP3A4 Inducers
flunarizine: they may diminish the serum concentration of CYP3A4 Inducers
melatonin: they may diminish the serum concentration of CYP3A4 Inducers
atosiban: they may diminish the serum concentration of CYP3A4 Inducers
alfuzosin: they may diminish the serum concentration of CYP3A4 Inducers
cannabis: they may enhance the serum concentration of CYP3A4 inducers
propofol: they may enhance the serum concentration of CYP3A4 inducers
tacrolimus: they may enhance the serum concentration of CYP3A4 Substrates
warfarin: they may enhance the serum concentration of CYP3A4 inducers
may diminish the rate of excretion when combined with each other
inducing agents of the cytochrome P450 enzymes, such as rifampin and carbamazepine, can reduce the exposure and effectiveness of rimonabant
an increase in rate of metabolism may be seen
an increase in rate of metabolism may be seen
When efavirenz is aided by hesperetin, it reduces hesperetin’s metabolism
may decrease the level of serum concentration
may decrease the level of serum concentration
may decrease the level of serum concentration
may decrease the level of serum concentration
may decrease the level of serum concentration
may decrease the level of serum concentration
tenofovir disoproxil fumarate or tenofovir DFÂ
may decrease the level of serum concentration
may decrease the level of serum concentration
may decrease the level of serum concentration
may decrease the level of serum concentration
relebactam: it may decrease the excretion of CYP3A inhibitors
cabotegravir: it may decrease the excretion of CYP3A inhibitors
capmatinib: it may decrease the excretion of CYP3A inhibitors
cefaclor: it may decrease the excretion of CYP3A inhibitors
cefalotin: it may decrease the excretion of CYP3A inhibitors
bumetanide: it may decrease the excretion of CYP3A inhibitors
diclofenac: it may decrease the excretion of CYP3A inhibitors
dolutegravir: it may decrease the excretion of CYP3A inhibitors
emtricitabine: it may decrease the excretion of CYP3A inhibitors
it may decrease the excretion of CYP3A inhibitors
ketoprofen: it may decrease the excretion of CYP3A inhibitors
fluprednisolone: it may increase the risk of adverse effects with CYP3A inhibitors
it may reduce the therapeutic effect
it may increase the levels of serum concentration
it may increase the levels of serum concentration
it may increase the levels of serum concentration
it may increase the levels of serum concentration
it may increase the levels of serum concentration
it may increase the levels of serum concentration
it may increase the levels of serum concentration
it may increase the levels of serum concentration
it may increase the levels of serum concentration
it may increase the levels of serum concentration
it may increase the levels of serum concentration
it may increase the levels of serum concentration
it may increase the levels of serum concentration
it may increase the levels of serum concentration
it may increase the levels of serum concentration
it may increase the levels of serum concentration
it may increase the levels of serum concentration
it may increase the levels of serum concentration
it may increase the levels of serum concentration
it may increase the levels of serum concentration
it may increase the levels of serum concentration
it may increase the levels of serum concentration
it may increase the levels of serum concentration
it may increase the levels of serum concentration
it may increase the levels of serum concentration
they increase the concentration of active metabolites of CYP3A4 inhibitors in the serum
they increase the concentration of active metabolites of CYP3A4 inhibitors in the serum
they increase the concentration of active metabolites of CYP3A4 inhibitors in the serum
they increase the concentration of active metabolites of CYP3A4 inhibitors in the serum
they increase the concentration of active metabolites of CYP3A4 inhibitors in the serum
Could potentially lead to a reduction in the concentration serum of hormonal contraceptives
Could potentially lead to a reduction in the concentration serum of hormonal contraceptives
Could potentially lead to a reduction in the concentration serum of hormonal contraceptives
Could potentially lead to a reduction in the concentration serum of hormonal contraceptives
Could potentially lead to a reduction in the concentration serum of hormonal contraceptives
it decreases the effect or level of finasteride by altering the intestinal/hepatic enzyme CYP3A4 metabolism
it decreases the effect or level of dutasteride by altering the intestinal/hepatic enzyme CYP3A4 metabolism
it decreases the concentration of hormonal contraceptives in serum
they increase the concentration of glasdegib in the serum
they increase the concentration of active metabolites of CYP3A4 inhibitors in the serum
they increase the concentration of active metabolites of CYP3A4 inhibitors in the serum
they increase the concentration of active metabolites of CYP3A4 inhibitors in the serum
they increase the concentration of active metabolites of CYP3A4 inhibitors in the serum
they increase the concentration of active metabolites of CYP3A4 inhibitors in the serum
CYP3A4 inhibitors increase the concentration of ubrogepant in the serum
CYP3A4 inducers decrease the concentration of opioids
CYP3A4 inducers decrease the concentration of opioids
CYP3A4 inducers decrease the concentration of opioids
CYP3A4 inducers decrease the concentration of opioids
CYP3A4 inducers decrease the concentration of hormonal contraceptives in the serum
CYP3A4 inducers decrease the concentration of hormonal contraceptives in the serum
CYP3A4 inducers decrease the concentration of hormonal contraceptives in the serum
CYP3A4 inducers decrease the concentration of hormonal contraceptives in the serum
Frequency defined:Â Â Â
>10%Â
Skin rashÂ
Increased serum cholesterol Â
1% to 10%:Â
Angina pectorisÂ
Facial edemaÂ
Myocardial infarctionÂ
SyncopeÂ
Peripheral neuropathyÂ
Abnormal dreamsÂ
AnxietyÂ
ConfusionÂ
DrowsinessÂ
DisorientationÂ
Disturbance in attentionÂ
NervousnessÂ
HypoesthesiaÂ
PrurigoÂ
Night sweatsÂ
XerodermaÂ
Diabetes Â
lipohypertrophyÂ
pancreatitisÂ
stomatitisÂ
anorexiaÂ
constipation Â
flatulence Â
gastritis Â
Post-marketing:Â
AngioedemaÂ
Erythema multiformeÂ
Hemorrhagic strokeÂ
RhabdomyolysisÂ
Stevens-Johnson syndromeÂ
Dress syndromeÂ
Pregnancy consideration: Efavirenz can moderately transfer across the human placenta.Â
Lactation: efavirenz can be excreted in breast milk. Â
Pregnancy category:Â
Patient information leafletÂ
Generic Name: Efavirenz Â
Pronunciation: efavirenz Â
Why do we use Efavirenz?Â
It is used to treat viral infections such as HIV-1 infection.
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
